Renaissance Technologies’s Caris Life Sciences CAI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10.1M Buy
568,000
+118,100
+26% +$2.11M 0.01% 1050
2026
Q1
$8.04M Buy
449,900
+120,000
+36% +$2.62M 0.01% 1093
2025
Q4
$8.9M Buy
329,900
+104,800
+47% +$2.95M 0.01% 978
2025
Q3
$6.81M Buy
+225,100
New +$7.18M 0.01% 1310

Other funds holding CAI

Renaissance Technologies's CAI Position: Q2 2026 in Review

Renaissance Technologies increased its Caris Life Sciences (CAI) stake by 26% in Q2 2026, buying an estimated $2.11M and bringing the position to 568,000 shares worth $10.1M. The position accounts for 0.01% of the portfolio, ranked #1050.

Renaissance Technologies first reported a position in CAI in Q3 2025 and has held it in 4 quarters since. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Renaissance Technologies held 568,000 shares of Caris Life Sciences worth $10.1M as of Q2 2026.
  • Renaissance Technologies bought 118,100 Caris Life Sciences shares in Q2 2026, an estimated $2.11M.
  • Caris Life Sciences made up 0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1050 holding.
  • Renaissance Technologies first reported a position in Caris Life Sciences in Q3 2025 and has held it in 4 quarters since.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.